The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Sorlate     2-[2-[3,5-bis(2- hydroxyethoxy)oxolan-2-yl]...

Synonyms: liposorb 0-20, SureCN15879, CHEMBL1697847, Tween(R) 80, LS-2298, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Polysorbate 80

  • Polysorbate 80 hypersensitivity [1].
  • Furthermore, it is not formulated with polyethylene glycol, polysorbate 80 (Tween; ICI Americas, Wilmington, DE), and ethanol, and does not cause acidosis when given at high doses [2].
  • Here, we investigated the biodistribution in the brain and in the body of poly(butyl-2-cyano[3-(14)C]acrylate) NP ([(14)C]-PBCA NP), polysorbate 80 (PS 80)-coated [(14)C]-PBCA NP, DOX-loaded [(14)C]-PBCA NP in glioblastoma 101/8-bearing rats after i.v. injection [3].
  • The method was subsequently used to measure concentrations of docetaxel and polysorbate 80 in plasma samples in support of a project to assess the influence of polysorbate 80 concentrations on the disposition and toxicity profile of docetaxel in cancer patients receiving Taxotere [4].
  • 4. Hemolysis testing as an in vitro assay indicated that LCC was safer than Polysorbate 80 (TO-10M) as intravenous surfactant in terms of induction of membrane damage [5].

High impact information on Polysorbate 80


Chemical compound and disease context of Polysorbate 80


Biological context of Polysorbate 80

  • Although vasodilatation of short duration caused by its solvent, polysorbate 80, also occurs, the overall cardiovascular changes are caused by the direct, intrinsic haemodynamic effects of amiodarone alone [15].
  • While the results of previous human studies have been rather variable, our investigations suggest that the cardiovascular changes following intravenous amiodarone include an early and usually short reduction of systemic and coronary vascular resistance, which may be partially due to the vasodilating properties of the solvent, polysorbate 80 [15].
  • Muscle exposed to polysorbate 80 (10 to 80 micrograms ml-1) showed a concentration-dependent lengthening of action potential duration (APD) but no detectable change in Vmax [16].
  • These results further support the hypothesis that the mechanism of blood-brain barrier transport of drugs by polysorbate 80-coated nanoparticles is one of endocytosis followed by possible transcytosis [17].
  • The results indicate that neither competitor displaced significant amounts of the parabens from their binding sites on polysorbate 80 [18].

Anatomical context of Polysorbate 80


Associations of Polysorbate 80 with other chemical compounds


Gene context of Polysorbate 80

  • The results show that only dalargin or loperamide-loaded nanoparticles coated with polysorbate 80 and/or with apolipoprotein B or E were able to achieve an antinociceptive effect [29].
  • CONCLUSION: At concentrations of PBCA nanoparticles and polysorbate-80 that achieve significant drug delivery to the brain, there is little in vivo or in vitro evidence to suggest that a generalized toxic effect on the BBB is the primary mechanism for drug delivery to the brain [30].
  • We have substituted cholesterol with fatty alcohols in niosomes containing polyglyceryl-3-di-isostearate (PGDS) and polysorbate-80 (PS-80) to explore their membrane-stabilizing property via permeation studies [31].
  • Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice [32].
  • RESULTS: For 2001 to 2003, the PRCA incidence rate for patients with subcutaneous exposure to Eprex in prefilled syringes with polysorbate 80 and uncoated rubber stoppers (leachates present) was 4.61/10,000 patient years (95% CI 3.88-5.43) versus 0.26/10,000 patient years (95% CI 0.007-1.44) for syringes with coated stoppers (leachates absent) [33].

Analytical, diagnostic and therapeutic context of Polysorbate 80


  1. Polysorbate 80 hypersensitivity. Shelley, W.B., Talanin, N., Shelley, E.D. Lancet (1995) [Pubmed]
  2. Etoposide phosphate: what, why, where, and how? Schacter, L. Semin. Oncol. (1996) [Pubmed]
  3. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. Ambruosi, A., Khalansky, A.S., Yamamoto, H., Gelperina, S.E., Begley, D.J., Kreuter, J. Journal of drug targeting. (2006) [Pubmed]
  4. Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Baker, S.D., Zhao, M., He, P., Carducci, M.A., Verweij, J., Sparreboom, A. Anal. Biochem. (2004) [Pubmed]
  5. Development of novel chitosan derivatives as micellar carriers of taxol. Miwa, A., Ishibe, A., Nakano, M., Yamahira, T., Itai, S., Jinno, S., Kawahara, H. Pharm. Res. (1998) [Pubmed]
  6. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Ng, S.S., Figg, W.D., Sparreboom, A. Cancer Res. (2004) [Pubmed]
  7. Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? Rhodes, A., Eastwood, J.B., Smith, S.A. Gut (1993) [Pubmed]
  8. Relationship of systemic exposure to unbound docetaxel and neutropenia. Baker, S.D., Li, J., ten Tije, A.J., Figg, W.D., Graveland, W., Verweij, J., Sparreboom, A. Clin. Pharmacol. Ther. (2005) [Pubmed]
  9. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Loos, W.J., Baker, S.D., Verweij, J., Boonstra, J.G., Sparreboom, A. Clin. Pharmacol. Ther. (2003) [Pubmed]
  10. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Olivier, J.C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., Couet, W. Pharm. Res. (1999) [Pubmed]
  11. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. Petri, B., Bootz, A., Khalansky, A., Hekmatara, T., Müller, R., Uhl, R., Kreuter, J., Gelperina, S. Journal of controlled release : official journal of the Controlled Release Society (2007) [Pubmed]
  12. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Gelperina, S.E., Khalansky, A.S., Skidan, I.N., Smirnova, Z.S., Bobruskin, A.I., Severin, S.E., Turowski, B., Zanella, F.E., Kreuter, J. Toxicol. Lett. (2002) [Pubmed]
  13. Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. Gough, W.B., Zeiler, R.H., Barreca, P., El-Sherif, N. J. Cardiovasc. Pharmacol. (1982) [Pubmed]
  14. Hypersensitivity reactions to etoposide. Hoetelmans, R.M., Schornagel, J.H., ten Bokkel Huinink, W.W., Beijnen, J.H. The Annals of pharmacotherapy. (1996) [Pubmed]
  15. Amiodarone. Haemodynamic profile during intravenous administration and effect on pacing-induced ischaemia in man. Remme, W.J., van Hoogenhuyze, D.C., Kruyssen, D.A., Krauss, X.H., Storm, C.J. Drugs (1985) [Pubmed]
  16. Alterations to the electrical activity of atrial muscle isolated from the rat heart, produced by exposure in vitro to amiodarone. Northover, B.J. Br. J. Pharmacol. (1984) [Pubmed]
  17. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. Alyaudtin, R.N., Reichel, A., Löbenberg, R., Ramge, P., Kreuter, J., Begley, D.J. Journal of drug targeting. (2001) [Pubmed]
  18. Effect of polyols on interaction of paraben preservatives with polysorbate 80. Blanchard, J. Journal of pharmaceutical sciences. (1980) [Pubmed]
  19. Action of fatty acids on the exocrine pancreatic secretion of the conscious rat: further evidence for a protein pancreatic inhibitory factor. Demol, P., Sarles, H. J. Physiol. (Lond.) (1978) [Pubmed]
  20. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Ramge, P., Unger, R.E., Oltrogge, J.B., Zenker, D., Begley, D., Kreuter, J., Von Briesen, H. Eur. J. Neurosci. (2000) [Pubmed]
  21. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. Salvatorelli, E., Menna, P., Cascegna, S., Liberi, G., Calafiore, A.M., Gianni, L., Minotti, G. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  22. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Azmin, M.N., Stuart, J.F., Florence, A.T. Cancer Chemother. Pharmacol. (1985) [Pubmed]
  23. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model. Seeballuck, F., Lawless, E., Ashford, M.B., O'Driscoll, C.M. Pharm. Res. (2004) [Pubmed]
  24. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Sun, W., Xie, C., Wang, H., Hu, Y. Biomaterials (2004) [Pubmed]
  25. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Kreuter, J., Alyautdin, R.N., Kharkevich, D.A., Ivanov, A.A. Brain Res. (1995) [Pubmed]
  26. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Alyautdin, R.N., Petrov, V.E., Langer, K., Berthold, A., Kharkevich, D.A., Kreuter, J. Pharm. Res. (1997) [Pubmed]
  27. In vitro-in vivo myotoxicity of intramuscular liposomal formulations. al-Suwayeh, S.A., Tebbett, I.R., Wielbo, D., Brazeau, G.A. Pharm. Res. (1996) [Pubmed]
  28. Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. Sanchez De Juan, B., Von Briesen, H., Gelperina, S.E., Kreuter, J. Journal of drug targeting (2006) [Pubmed]
  29. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., Alyautdin, R. Journal of drug targeting. (2002) [Pubmed]
  30. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Kreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S.E., Engelhardt, B., Alyautdin, R., von Briesen, H., Begley, D.J. Pharm. Res. (2003) [Pubmed]
  31. Release studies on niosomes containing Fatty alcohols as bilayer stabilizers instead of cholesterol. Devaraj, G.N., Parakh, S.R., Devraj, R., Apte, S.S., Rao, B.R., Rambhau, D. Journal of colloid and interface science. (2002) [Pubmed]
  32. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. van Tellingen, O., Beijnen, J.H., Verweij, J., Scherrenburg, E.J., Nooijen, W.J., Sparreboom, A. Clin. Cancer Res. (1999) [Pubmed]
  33. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Boven, K., Stryker, S., Knight, J., Thomas, A., van Regenmortel, M., Kemeny, D.M., Power, D., Rossert, J., Casadevall, N. Kidney Int. (2005) [Pubmed]
  34. Mechanism by which a sustained inflation can worsen oxygenation in acute lung injury. Musch, G., Harris, R.S., Vidal Melo, M.F., O'Neill, K.R., Layfield, J.D., Winkler, T., Venegas, J.G. Anesthesiology (2004) [Pubmed]
  35. Rate-limiting steps in oral absorption of a leucotriene D4 antagonist in the beagle dog. Kararli, T.T., Stolzenbach, J. Journal of pharmaceutical sciences. (1992) [Pubmed]
  36. Determination of polysorbate 80 in parenteral formulations by high-performance liquid chromatography and evaporative light scattering detection. Nair, L.M., Stephens, N.V., Vincent, S., Raghavan, N., Sand, P.J. Journal of chromatography. A. (2003) [Pubmed]
  37. High-performance liquid chromatographic determination of polysorbate 80 in pharmaceutical suspensions. Hu, M., Niculescu, M., Zhang, X.M., Hui, A. Journal of chromatography. A. (2003) [Pubmed]
  38. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Ragupathi, G., Koide, F., Sathyan, N., Kagan, E., Spassova, M., Bornmann, W., Gregor, P., Reis, C.A., Clausen, H., Danishefsky, S.J., Livingston, P.O. Cancer Immunol. Immunother. (2003) [Pubmed]
WikiGenes - Universities